Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.
Ortigas
Melina C
MC
Bourgeois
James A
JA
Schneider
Andrea
A
Olichney
John
J
Nguyen
Danh V
DV
Cogswell
Jennifer B
JB
Hall
Deborah A
DA
Hagerman
Randi J
RJ
D000368:Aged; D001259:Ataxia / Q000188:drug therapy* / Q000209:etiology; D003511:Cyclohexanols / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008559:Memantine / Q000008:administration & dosage*; D014202:Tremor / Q000188:drug therapy* / Q000209:etiology; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D051860:Fragile X Messenger Ribonucleoprotein 1; D008559:Memantine; D000069470:Venlafaxine Hydrochloride; C497683:FMR1 protein, human